Publications by authors named "D Dorcaratto"
Article Synopsis
- International guidelines for imaging follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC) are inconsistent, leading to varied follow-up strategies globally.
- The study aimed to compare clinical outcomes, including treatment for recurrence and survival rates, between patients who received either symptomatic follow-up or routine imaging after PDAC surgery across 33 international centers.
- A total of 333 patients were analyzed, showing that 29% had symptomatic follow-up while 71% underwent routine imaging, with overall survival rates being examined through statistical methods to identify the impact of the follow-up strategy on patient outcomes.
Activated hepatic stellate cells (aHSCs), the main perpetrators of liver fibrosis, are a promising therapeutic target in the treatment of chronic liver disease. During liver injury, HSCs transcend from a quiescent to a fibrotic phenotype, a process which involves major metabolic reprogramming with altered mitochondrial function. The antiretroviral drug Rilpivirine (RPV) has demonstrated a hepatoprotective and specifically antifibrotic effect in several animal models of chronic liver injury, as well as in vitro.
View Article and Find Full Text PDFA machine learning predictive model for recurrence of resected distal cholangiocarcinoma: Development and validation of predictive model using artificial intelligence.
Eur J Surg Oncol
July 2024
Introduction: Distal Cholangiocarcinoma (dCCA) represents a challenge in hepatobiliary oncology, that requires nuanced post-resection prognostic modeling. Conventional staging criteria may oversimplify dCCA complexities, prompting the exploration of novel prognostic factors and methodologies, including machine learning algorithms. This study aims to develop a machine learning predictive model for recurrence after resected dCCA.
View Article and Find Full Text PDFctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.
Transl Res
September 2024
Article Synopsis
- Understanding how pancreatic ductal adenocarcinoma (PDAC) progresses and developing targeted therapies is crucial, and this study involved 80 metastatic PDAC patients divided into discovery and validation groups to examine genetic variants.
- Whole exome sequencing (WES) of tumor and plasma samples highlighted that actionable mutations were more prevalent in plasma, and associations with cellular organization pathways were found in patients with shorter survival.
- Notably, KRAS mutations in plasma were linked to worse progression free survival, while significant reductions in KRAS variant allele frequency correlated with improved outcomes similar to KRAS-negative patients, emphasizing the relevance of immune response pathways in liver metastasis.
Article Synopsis
- * Conducted between June 2019 and August 2020, the retrospective analysis involved 40 hospitals, with insights derived from over 2,200 liver surgeries, including 1350 for colorectal metastases, of which 150 utilized the liver-first strategy.
- * Findings revealed no significant differences in surgical outcomes between hospitals performing fewer than 50 versus those performing 50 or more liver surgeries per year, prompting further research into optimal candidate selection for this treatment approach.